Arcus Climbs On Positive Results In Joint TIGIT Program In ARC-7 Study

Arcus Biosciences, Inc. (RCUS) shares are gaining more than 10 percent on Monday morning after the company jointly with Gilead Sciences, Inc. (GILD) announced positive results from an open-label TIGIT Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer.

ARC-7 evaluated the combinations of anti-TIGIT antibody domvanalimab plus anti-PD-1 antibody zimberelimab, domvanalimab plus zimberelimab and etrumadenant, an A2a/b adenosine receptor antagonist, versus zimberelimab alone.

Domvanalimab combinations continued to show clinically meaningful differentiation compared to zimberelimab monotherapy across multiple efficacy measures.

A total of 150 patients have been randomized across the three study arms.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT